Liver cancer represents the sixth most common cancer worldwide. The extremely poor prognosis makes it rank the third in cancer-related deaths. Despite the current improvements, therapeutic methods for liver cancer are still limited and the outcome remains unsatisfactory. This dilemma is at least partly because of the lack of well-characterized molecular targets and effective interventions. Advancements in mechanism of liver cancer have shed light on the pathogenesis of this disastrous disease and provided promising targets for the development of next-generation therapies. With proper structures, some small molecules may combine ideal bioavailability and selective therapeutic effects. Compound screening based on molecular targets leads to the innovation of numerous novel interventions for liver cancer. Among them, the multikinase inhibitor sorafenib has become first-line therapy for advanced-stage hepatocellular carcinoma and significantly improved the outcome. Exploiture of ethnic medicine also revealed a large resource of small molecules for the treatment of liver cancer from well-established regimens. The combination of key molecules and small compound interventions has been proven effective. Upcoming research on novel molecular targets and discovery of targeted small molecules for liver cancer will have distinguished significance in novel drug development and may have direct impact on clinical management.

We invite authors to contribute original research and review articles that will stimulate the lasting exertion to unveil novel molecular targets and small molecular interventions for liver cancer. Potential topics include, but are not limited to:

• Novel molecular targets in carcinogenesis, progression, and metastasis of liver cancer
• Clinical significance of molecular pathways in liver cancer
• Screening and evaluation of potential diagnostic or therapeutic small molecules
• Structural design and chemical modification of small molecules
• Small radioactive molecules for liver cancer
• Pharmacodynamics, pharmacokinetics, and toxicology of small molecules
• Clinical evaluation of small molecular targeted interventions for liver cancer
• Novel integrative and multimodal therapy with small molecules
• Ethnopharmacology in liver cancer therapy

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/gastroenterology/ntsi/ according to the following time table: